Logo image
Emergent use of anticoagulation for treatment of patients with ischemic stroke
Journal article   Open access   Peer reviewed

Emergent use of anticoagulation for treatment of patients with ischemic stroke

Harold P Adams Jr
Stroke (1970), Vol.33(3), pp.856-861
03/2002
DOI: 10.1161/hs0302.104628
PMID: 11872915
url
https://doi.org/10.1161/hs0302.104628View
Published (Version of record) Open Access

Abstract

Several clinical trials have tested the potential utility of emergent anticoagulation for acute ischemic stroke. Rather than performing a meta-analysis that combines the data from several trials, this review focuses on individual studies. Although these trials do have inherent limitations, they demonstrate that emergent use of an anticoagulant is associated with a modest but significantly increased risk of hemorrhagic transformation of the ischemic stroke or serious nonneurological bleeding. The trials do not demonstrate a benefit from emergent anticoagulation in improving outcome, reducing mortality, and preventing early recurrent stroke. These results suggest that most patients with acute stroke should not be treated with unfractionated heparin or other rapidly acting anticoagulants after stroke. Prevention of deep vein thrombosis and pulmonary embolism among bedridden patients is the only established indication for early anticoagulation after acute ischemic stroke.
Brain Ischemia - complications Humans Cerebral Hemorrhage - mortality Stroke - complications Anticoagulants - therapeutic use Clinical Trials as Topic Secondary Prevention Stroke - drug therapy Anticoagulants - adverse effects Disease Progression Brain Ischemia - drug therapy Emergency Treatment - adverse effects Cerebral Hemorrhage - prevention & control Brain Ischemia - mortality Stroke - mortality Cerebral Hemorrhage - etiology

Details

Metrics

Logo image